Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors

Published:2021-02-20 Issue:7 Volume:131 Page:
ISSN:0023-852X
Container-title:The Laryngoscope
language:en
Short-container-title:The Laryngoscope

Author:

Leddon Jennifer L.¹²^ORCID,Chirra Martina¹³,Frankart Andrew J.⁴,Agrawal Arushi⁴,Roof Logan¹,Trotier Danny¹,Shaikh Hira¹,Stone Timothy⁵,Jandarov Roman⁵,Takiar Vinita⁴⁶^ORCID,Wise‐Draper Trisha M.¹

Affiliation:

1. Division of Hematology Oncology, Department of Medicine University of Cincinnati Medical Center Cincinnati OH U.S.A.

2. Department of Internal Medicine, Clinical Scientist Training Program University of Cincinnati Cincinnati OH U.S.A.

3. Division of Nephrology, Department of Internal Medicine University of Cincinnati Cincinnati OH U.S.A.

4. Department of Radiation Oncology University of Cincinnati Medical Center Cincinnati OH U.S.A.

5. Division of Biostatistics and Bioinformatics, Department of Environmental Health University of Cincinnati Cincinnati OH U.S.A.

6. Department of Radiation Oncology Cincinnati VA Medical Center Cincinnati OH U.S.A.

Funder

University of Cincinnati

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lary.29451

Reference26 articles.

1. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

4. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma;Oral Oncology;2024-02

2. Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review;Journal of Clinical Medicine;2023-08-07

3. Toxicity When Combining Immunotherapy and Radiotherapy;Handbook of Cancer and Immunology;2023

4. Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment;Anticancer Research;2022-08-23

5. Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis;Reports of Practical Oncology and Radiotherapy;2022-05-19